Pharmacodynamically guided dose selection of PF-00337210, a VEGFR2 tyrosine kinase (TK) inhibitor, in a phase I study.

3033 Background: PF-00337210 is a highly potent and selective ATP-competitive inhibitor of VEGFR2 TK with a cellular IC50 of 0.8 nM. In vivo, it inhibits tumor angiogenesis and human xenograft grow...